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ABSTRACT

Antimicrobials are essential in the treatment of diseases in both humans and
animals, but antimicrobial resistance threatens their efficacy. As more microorganisms
become resistant to an ever-growing list of antimicrobials, diseases that used to be simple
to treat are becoming increasingly difficult to manage. The major factors contributing to
antimicrobial resistance are overuse and misuse of antimicrobials. In order to combat the
problem of resistance, antimicrobial stewardship programs that aim to improve
antimicrobial prescribing and use practices are becoming increasingly widespread. These
programs are quite common in human medicine, but the COVID-19 pandemic disrupted
many aspects of life, including antimicrobial stewardship. In this study, three classes of
antibacterials, beta-lactams, macrolides, and fluoroquinolones, will be reviewed as well
as two antiparasitic classes, quinolines and avermectins, before investigating the effect
the COVID-19 pandemic has had on antimicrobial stewardship in human medicine. The
aim of this study is to assess the impact the pandemic had on these programs, and
whether this decreased their effectiveness in reducing the behaviors and practices
associated with the development of antimicrobial resistance. This information will then
be applied to veterinary medicine using a One Health perspective, which recognizes that
human, animal, and environmental health are intimately connected.
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INTRODUCTION

The COVID-19 pandemic has had substantial effects on the healthcare system.
These effects also have the potential to impact veterinary medicine because human and
animal health are closely interrelated. One key aspect of human and animal health is
antimicrobial use. The COVID-19 pandemic affected the use of these medicines by
disrupting clinical service delivery, changing the antimicrobial supply chain, contributing
to misinformation, and leading to the overtreatment of COVID-19 patients with
antibacterials (Lynch et al., 2020). The effects brought about by the pandemic have the
potential to affect antimicrobial use in veterinary medicine by changing the availability of
certain drugs and increasing antimicrobial resistance in both humans and animals.
Humans and animals are often treated with the same medicines and a decrease in
the availability of certain antimicrobials can lead to animals being more at risk of disease
complications and inadequate treatment. The development of antimicrobial resistance is
also a threat to both human and animal health. Antimicrobial resistance is correlated with
increased economic costs and more severe infections in humans and animals (Bengtsson
& Greko, 2014; CDC, 2019). Some of the major strains of resistant bacteria that infect
both humans and animals are methicillin-resistant Staphylococcus aureus (MRSA), other
methicillin-resistant staphylococci, vancomycin-resistant enterococci, carbapenemaseproducing enterobacteria, and extended-spectrum beta-lactamase (ESBL) Gram-negative
bacteria (Palma et al., 2020). Human infections associated with these strains can lead to
worse health outcomes, increased medical costs, and increased risk of death (CDC,
2019).
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The changes in antimicrobial use brought about by the COVID-19 pandemic can
have serious effects on veterinary medicine by contributing to the development of
resistance in microorganisms. A decrease in the availability of certain antimicrobials for
animal use can lead to the incorrect drug being used to treat infections. This can lead to
the development of resistance since inappropriate antimicrobial use can allow some
microorganisms to survive. The increase in antimicrobial use in humans can also increase
antimicrobial resistance. As many microorganisms are capable of sharing their resistance
with other strains through mechanisms of horizontal gene transfer, antimicrobial
resistance can be spread to a wide variety of microorganisms. This can also lead to
microorganisms that infect animals to also develop resistance. As animals rely on humans
for their healthcare, increases in antimicrobial resistance in human pathogens can also
lead to increases in animal diseases and decreases in animal welfare. Increases in human
healthcare costs, longer hospital stays, and more serious infections can lead to people not
having the resources available to care for their animals.
This review aims to assess how the COVID-19 pandemic has affected
antimicrobial use in human medicine. This information will then be used to assess the
possible impacts that changes in human medicine could have on veterinary medicine. The
results will then be used to understand how the COVID-19 pandemic affected the
development of antimicrobial resistance and highlight the importance of considering the
interdependence of human and veterinary medicine.
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METHODOLOGY

The information gathered in this literature review was obtained by utilizing the
University of Maine’s Raymond H. Fogler Library using the One Search database
function and the United States Center for Disease Control website. The CDC’s website
was used exclusively for investigating the recommendations for COVID-19 treatments,
and the One Search databases were used for all other searches. The search terms used
include “antimicrobials”, “antibiotics”, “antibacterials”, “antiparasitics”, “COVID-19”,
“pandemic”, “resistance”, “One Health”, “veterinary”, “stewardship”, “beta-lactams”,
“macrolides”, “fluoroquinolones”, “quinolines”, “avermectins”, “ivermectin”, and
“hydroxychloroquine.”

3

WHAT ARE ANTIMICROBIALS?

Antimicrobials are substances that are used to treat a variety of diseases by killing
or inhibiting the growth of certain microorganisms (WHO, 2020). Antimicrobials are
often divided into antibacterials, antivirals, antifungals, and antiparasitics, each of which
is further divided into subcategories. It should be noted that one substance can have
several properties, such as being antibacterial and antiparasitic. While the term antibiotic
is often used interchangeably with antibacterial, not all antibacterials are antibiotics. The
term antibiotic refers to an antimicrobial that is produced naturally by microorganisms to
inhibit the growth of another microorganism. Antibiotics can have antibacterial, antiviral,
antifungal, or antiparasitic activity. An example of an antibiotic that is also an
antibacterial is penicillin, which is produced by the fungus Penicillium to inhibit the
growth of bacteria, though today penicillin is also produced synthetically (Lowe, 2020).
For the purposes of this review, the term antibiotic will not be used to refer to
antibacterials, but it should be noted that this is a common practice (WHO, 2019). Figure
one displays a diagram that highlights the relationship between the key terms regarding
antimicrobials.
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Figure 1. Visual representation of the relationship between key terms regarding
antimicrobials

Antimicrobials are critically important for the treatment of infectious diseases,
and their discovery led to a large global decline in mortality. From 1938 to 1952, the
infectious disease mortality rate in the United States declined by 8.2% each year as a
result of antimicrobial use (Aminov, 2017). As of 2019, antibacterials were the most
commonly prescribed drugs in hospitals worldwide (Yimenu et al., 2019). These drugs
have contributed to safer childbirth, surgical procedures, and organ transplants (Marston
et al., 2016). In addition to their applications in human health, antimicrobials are used in
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the maintenance of animal welfare by treating and preventing diseases (Landers et al.,
2012). As the use of antibacterials and antiparasitics was most affected by the COVID-19
pandemic, they will be the focus of this paper. The effects of the COVID-19 pandemic on
antibacterial use are largely related to the fact that antibacterials were commonly
prescribed to individuals suffering from COVID-19 to combat possible secondary- or cobacterial infections (Langford et al., 2020). Antiparasitic use was also affected as there
was research into the antiviral properties of several antiparasitics. These studies have
focused on the possible uses of hydroxychloroquine and ivermectin in treating COVID19, however, the CDC has stated that there is not enough evidence to support their use
(“Chloroquine or hydroxychloroquine”, 2021; “Ivermectin”, 2021). Despite this, some
people still used these drugs to treat COVID-19. The three antibacterial classes covered
are beta-lactams, macrolides, and fluoroquinolones. Two antiparasitic classes, quinolines
and avermectins, will be discussed.
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WHAT IS ANTIMICROBIAL RESISTANCE?

Antimicrobials are invaluable in protecting human and animal health, but the
effectiveness of these drugs is becoming increasingly threatened. Microorganisms have
adapted, and some have developed antimicrobial resistance (AMR) and are no longer
affected by the antimicrobials we rely on to save lives. The situation is so dire that the
WHO named AMR as one of the top ten global public health threats to humanity
(“Antimicrobial Resistance”, 2020). Antimicrobial resistance is a global threat that
crosses country and species lines as the vast majority of antimicrobial classes are used in
human, animal, and plant applications (McEwen & Collignon, 2018).

Factors Contributing to Antimicrobial Resistance
Antimicrobial resistance develops through the process of natural selection. Some
microorganisms have genes that allow them to be unaffected by the antimicrobial, and
these microorganisms survive while those who are affected by the antimicrobial die when
antimicrobials are used. Figure two demonstrates how the use of antimicrobials can lead
to resistant organisms being the dominant strain. It should be noted that for simplicity
figure two does not take into account the effects of the host’s immune system. The
immune system also acts against pathogenic microorganisms, which reduces the chances
of antimicrobial use contributing to the development of antimicrobial resistance by
eliminating resistant organisms.
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Figure 2. Selection of resistant microorganisms when antimicrobials are used

There are many factors that contribute to the development of AMR. The first is
that many microorganisms reproduce quickly. For example, the bacterium
Staphylococcus aureus can replicate and reproduce roughly every half hour. This means
that in less than twelve hours, their numbers can increase by over one million-fold
(Marston et al., 2016). Each replication provides the chance for new mutations to develop
in the microorganism’s genome, and their rapid generation time allows them to quickly
evolve to overcome the effects of antimicrobials.
When antimicrobials are used, the organisms present undergo selection pressure,
and only those that are resistant survive. The resistant organisms are then able to
reproduce and quickly grow in numbers while the non-resistant organisms die, as seen in
figure two. This selection process forms the basis for the development of AMR.
Human behavior arguably has the greatest effect on the development of AMR.
While the genetics of the microorganisms is what confers resistance, antimicrobial use
8

selects for the organisms that are resistant. Some factors that contribute to the
development of AMR include over-use of antimicrobials, misuse of antimicrobials, poor
disease prevention, and inadequate access to vaccines and medicine. (WHO, 2020). Overusing antimicrobials provides more chances that a microorganism will be exposed to the
antimicrobial and lead to the selection of resistant individuals. Similarly, misuse of
antimicrobials can lead to the development of resistance since the antimicrobial may not
be used in a way that will ensure the elimination of the microorganism. This can lead to
more microorganisms surviving the exposure and developing resistance. Also, if the
incorrect antimicrobial is used, it can select for resistant microorganisms that are not the
ones causing the disease. These species can then transfer their resistance to other species,
as discussed in the next section. Poor disease prevention can lead to the development of
AMR because if a disease is prevented, there would be less use of antimicrobials to
which the microorganism could be exposed. Preventing the disease limits the use of
antimicrobials and therefore the chances of selecting for resistant organisms.

Mechanisms of Antimicrobial Resistance Sharing
All organisms are capable of vertical gene transfer, which refers to the transfer of
genetic information from the parent or parents to their offspring. This allows for
resistance genes to be passed on to the next generation. In addition to vertical gene
transfer, microorganisms, particularly bacteria, have mechanisms that allow them to share
their resistance with other individuals through horizontal gene transfer. In horizontal gene
transfer, genetic information is shared with other individuals that may or may not be of
the same species. In bacteria, antimicrobial resistance genes are often found on plasmids,
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and bacteria can share DNA on these structures with each other. As plasmids are found in
a variety of bacterial species, this allows for resistance to be shared between different
species (Marston et al., 2016). In conjugation, a bacterium will replicate its plasmid and
transfer one copy to another bacterial cell. If this plasmid contained a gene that confers
resistance, both bacteria are now resistant (Graf et al., 2018).
Bacteria can also acquire resistance genes through phage-mediated transduction,
where a virus called a bacteriophage transfers bacterial DNA into a bacterium. The
bacterial DNA that was transferred by the virus may contain genes for resistance, which
leads to the spread of AMR. Transformation is a process where bacteria can take up DNA
in their environment, which also has the potential to lead to the development of resistance
(Graf et al., 2018). Some bacteria also possess mobile genetic elements, like transposons
that are capable of moving within and between bacterial cells (Johansson et al., 2020). As
these genetic sequences can move between the chromosomes and plasmids of different
bacteria, they can confer resistance on more bacteria (Babakhani & Oloomi, 2018).

Problems Associated with Antimicrobial Resistance
Antimicrobial resistance is harmful in regard to human and animal health as well
as in relation to economic costs. According to the CDC’s 2019 AR threat report, more
than 2.8 million antibiotic-resistant infections occur in the United States each year, and
more than 35,000 people die from these infections (CDC, 2019). Antimicrobial resistance
makes diseases more difficult to treat and correlates to worse health outcomes.
Antimicrobials are also important for other medical procedures. Chemotherapy, organ
transplants, surgeries, and intensive care treatment all depend on the availability of
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effective antimicrobials. The effects on animal health are also considerable as
antimicrobial resistance can lead to more complicated treatment and higher rates of
euthanasia and death (Bengtsson & Greko, 2014).
In addition to its effects on health, antimicrobial resistance also has a large
economic impact. In 2013, the CDC estimated that AMR cost the U.S. $55 billion in
excess health care costs and lost productivity (Prestinaci et al., 2015). Similar increases in
costs are associated with antimicrobial resistance in animals. There are also other costs
associated with AMR in animals. Money spent training and raising the animals,
particularly in horses, service animals, and production animals, is lost upon the animal’s
death (Bengtsson & Greko, 2014).
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WHAT IS ANTIMICROBIAL STEWARDSHIP?

The goal of antimicrobial stewardship programs, also called antibiotic
stewardship programs, is to measure and improve the use of antimicrobials in order to
effectively treat infections, prevent harm caused by unnecessary antimicrobial use, and
combat antimicrobial resistance (CDC, 2021b). In order to treat infections, an
antimicrobial that is appropriate and effective needs to be selected. Similarly, many
antimicrobials have adverse side effects, so they should only be used when necessary.
Ensuring the appropriate use of antimicrobials helps to maximize positive patient
outcomes while limiting possible negative side effects. As overuse and misuse of
antimicrobials contribute to antimicrobial resistance, these steps also help to prevent the
development of resistance.
The responsible use of antimicrobials involves ensuring that the right
antimicrobial is prescribed and taken for the correct amount of time. This is done through
a combination of providing guidelines and education to medical professionals, patients,
and the community (Doron & Davidson, 2011). Prescribers should ensure that they are
making accurate diagnoses and following antimicrobial guidelines (Dyar et al., 2017).
Antimicrobial stewardship programs can be found in hospitals, communities, veterinary
practices, and the WHO global stewardship framework (Dyar et al., 2017). The CDC
identifies seven core elements of antimicrobial stewardship, which are Leadership,
Accountability, Pharmacy expertise, Action, Tracking, Reporting, and Education (CDC,
2021c). Figure three shows the percentage of hospitals by state that met all seven of these
elements in 2019 (CDC, 2021a).

12

Figure 3. Percentage of hospitals that met all seven CDC core elements of antimicrobial
stewardship in 2019 (CDC, 2021a)
While the CDC does not require the presence of clinical microbiologists on
antimicrobial stewardship teams, the inclusion of these individuals can greatly increase
the success of these programs. This increase in success is related to providing patientspecific culture and susceptibility data that can be used to identify the pathogen and
which antimicrobials it is susceptible to. A survey of hospitals in Quebec found that 89%
of hospitals included a clinical microbiologist in their stewardship programs while other
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surveys have found that only 26% of hospitals in California and 42% of hospitals in
Florida included microbiologists in their stewardship programs, indicating that
stewardship programs can still be improved (Morency-Potvin et al., 2017). The use of
antimicrobial sensitivity tests, which are more common in veterinary medicine than in
human medicine, would improve the use and effectiveness of antimicrobials which would
help to limit the development of antimicrobial resistance. It would also improve the
health outcomes of patients by providing more effective treatment (Khan et al., 2019).
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THE ONE HEALTH PERSPECTIVE

The universal use of antimicrobials and the interconnectedness of human, animal,
and environmental health has led to the development of a One Health approach to address
many health-related problems, including antimicrobial resistance. One Health refers to a
collaborative cross-disciplinary approach to obtain optimal health for humans, domestic
animals, wildlife, plants, and the environment (McEwen & Collignon, 2018). The One
Health perspective takes into account that antimicrobial resistance in one sector can
impact all of the others. This is true of both human and veterinary medicine.
Humans and animals are infected with many of the same species of
microorganisms. Zoonotic diseases, or zoonoses, are diseases that are caused by
organisms that can spread between animals and humans. It is estimated that every six out
of ten known diseases are zoonotic and three out of every four new or emerging
infections in humans originate from animals. Some examples of zoonoses are influenza,
salmonellosis, West Nile virus, rabies, Lyme disease, and COVID-19 (CDC, 2021d).
One example of how the environment influences human and veterinary medicine is
the presence of natural resistance in organisms in the environment. Mechanisms of
resistance to penicillins were discovered in soil bacteria years before penicillins were
clinically used in humans. Bacterial modes of horizontal gene transfer allow for these soil
organisms to transmit their resistance genes to other bacterial species that can cause
disease. The rapid increase in AMR to penicillins likely had its foundations in the
presence of these genes in soil organisms that were exposed to these compounds by the
fungi with which they shared an environment (Fernandes et al., 2013).
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Antimicrobial use in human and veterinary medicine can also affect the
environment. Fluoroquinolones are widely used in both animal and human medicine,
which can lead to their introduction into the environment. Unused medications can be
improperly disposed of and end up in wastewater, and a certain amount of these
antibacterials end up in the feces of those treated with them. Spreading manure and
sewage sludge to agricultural fields is a common practice that can introduce these drugs
into the environment. Resistant pathogenic bacteria have been detected in wastewater and
sewage-treatment plants (Picó & Andreu, 2006). These bacteria can then infect animals
and confer their resistance genes to other bacteria. Plants can also take up these chemicals
from the soil and their presence has been detected in carrots and lettuce (Boxall et al.,
2006). In the United States and Spain where fluoroquinolones are commonly used in
animals, high rates of resistance, sometimes over 80%, have been detected in food-borne
pathogens. In Australia, where fluoroquinolones are not approved for animal use,
fluoroquinolone resistance rates in these pathogens were significantly lower, indicating
that human and animal health are closely related (Pham et al., 2019).
Animals share the same environment as humans and often the same infections
(McEwen & Collignon, 2018). The same antimicrobials are used in almost all
applications and microorganisms have developed ways to share resistance both among
and between species. In order to ensure that antimicrobials stay effective, antimicrobial
use must be monitored in human, animal, and environmental health sectors. Figure four
shows how antimicrobial resistance organisms and genes can spread (Walsh, 2018).
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Figure 4. Antimicrobial resistance can spread between humans, animals, and the
environment (Walsh, 2018).
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ANTIBACTERIALS

Antibacterials are a class of antimicrobials that kill or inhibit the growth of
bacteria. As of 2019, antibacterials were the most commonly prescribed drugs in
hospitals worldwide (Yimenu et al., 2019). The three antibacterial classes that will be
reviewed in this paper are beta-lactams, macrolides, and fluoroquinolones. All three
classes are used in both human and veterinary medicine. These three classes were chosen
because they are all important in the treatment of both humans and animals and are
widely used.

Beta-lactams
Beta-lactams are the most widely used class of antibacterials, accounting for 65%
of all prescriptions of injectable antibacterials in the U.S. (Bush & Bradford, 2016). Betalactams are characterized as having a beta-lactam ring, which is a four-cornered ring
containing a nitrogen atom (Fernandes et al., 2013). Some beta-lactams have sidechains
connected to the ring, and a small percentage of patients have an allergic reaction to betalactams due to these side-chain determinants. Penicillin G was the first beta-lactam to be
used clinically. Some examples of beta-lactams are penicillins, cephalosporins,
monobactams, and carbapenems (Bush & Bradford, 2016).
Beta-lactams are broad-spectrum antibacterials that are widely used in both
human and veterinary medicine to treat and prevent infections caused by bacteria. They
are effective against many bacteria, including Streptococcus and Staphylococcus species,
Gram-positive, Gram-negative, enteric, and anaerobic bacteria (Bush & Bradford, 2016).
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They have also been used to improve growth rate and feed efficiency in food animals (Li
et al., 2007). The basis for their growth-promoting effect is not known, but some
hypotheses include that the antibacterial works against microorganisms present in the
animal feed that consume some nutrients, inhibit the absorption of nutrients, or negatively
impact the animal’s health (Chattopadhyay, 2014). Beta-lactams are listed on the World
Health Organization’s (WHO) list of critically important antimicrobials for human
medicine and the World Organization for Animal Health’s (OIE) list of antimicrobials of
veterinary importance (OIE, 2021; WHO, 2019).

Mechanism of Action
Almost all bacteria cells have a cell wall that functions to maintain the shape of
the cell and withstand intracellular pressure. These cell walls are made of peptidoglycan,
which is found only in bacterial cells (Scheffers & Pinho, 2005). Beta-lactams interfere
with the formation of the cell wall by binding to penicillin-binding proteins, which are
enzymes essential for peptidoglycan cross-linking (Bush & Bradford, 2016). The
enzymes become non-functional, and the bacteria cannot build their cell wall. As bacteria
cannot survive without their cell wall, this results in their death.

Resistance
As beta-lactams have been widely used for many years, bacteria have developed
resistance to them. Resistance to beta-lactams developed rapidly. Six years after its
introduction to the market, resistance to benzylpenicillin in staphylococci went from less
than 10% to 60%, and resistance is found in over 90% of staphylococci today (Fernandes

19

et al., 2013). The most common form of resistance is the presence of beta-lactamases in
bacteria. These enzymes alter the beta-lactam ring of the antibacterial, which renders
them ineffective. Many of the genes associated with beta-lactamases are found on
plasmids and transposons, which facilitates the spread of resistance to other bacterial
species (Fernandes et al., 2013). In order to combat this resistance problem, betalactamase inhibitors were developed that prevent the beta-lactamase enzyme from
altering the beta-lactam ring (Bush & Bradford, 2016).
Another form of resistance involves the alteration of the structure of the
penicillin-binding proteins so that they are not affected by the binding of a beta-lactam.
These altered penicillin-binding proteins are still functional even in the presence of betalactams. Some bacterial cells have developed resistance by developing efflux pumps that
actively remove the antibacterial from the cytoplasm or alterations in the cell membrane
that limit beta-lactams from entering in the first place (Fernandes et al., 2013).

Macrolides
Macrolides are a group of compounds that are made up of a 12-, 14-, 16-, or 17membered macrocyclic lactone ring with various attachments that have antibacterial
activity. They were first isolated from a Streptomyces bacterial strain (Dinos, 2017).
Macrolides are the second most prescribed antibacterial class in the United States, and
azithromycin was the most prescribed antibacterial agent (Hicks et al., 2015). Other
macrolides are erythromycin, clarithromycin, and fidaxomicin. Macrolides have a slightly
broader spectrum of activity than beta-lactams, and they are often used in those with
penicillin allergies (Aminov, 2017).
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Macrolides are broad-spectrum antibacterials that are widely used in both human
and veterinary medicine. Their uses in human medicine include infections caused by
Mycoplasma species, Chlamydia species, and some Gram-negative bacteria. Veterinary
applications include preventing and treating bovine respiratory disease complex and
mastitis in cattle as well as a variety of other bacterial infections in companion animals,
swine, and sheep (Anadón & Reeve-Johnson, 1999; Trott et al., 2021). Macrolides are
listed as critically important antimicrobials on both the WHO’s list of critically important
antimicrobials for human medicine and the OIE’s list of antimicrobials of veterinary
importance (OIE, 2021; WHO, 2019).

Mechanism of Action
All cells need to be able to create proteins in order to perform the functions
necessary for life. Macrolides interfere with this process and disrupt protein synthesis.
The macrocyclic lactone ring of the macrolide binds to the 50S ribosomal subunit and
blocks where newly synthesized proteins are released. The macrolide disrupts protein
synthesis by either disrupting peptide bond formation in the protein or inhibiting
elongation of the peptide through steric hindrance (Lenz et al., 2021). As the bacteria can
no longer synthesize the proteins it requires, it will be unable to divide and will die.

Resistance
Bacteria have developed resistance to macrolides through two main mechanisms.
The first is through modification of the ribosomes to prevent the macrolide from binding.
Some bacteria add methyl groups to the binding site of the macrolide, which prevents the
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macrolide from binding there and preventing protein synthesis. Nearly forty genes
associated with this type of resistance have been identified and many are found on
plasmids and transposons. Other bacteria have mutations in the genes that code for the
part of the ribosome that macrolides bind to. This mutation alters the structure enough so
that the macrolide cannot attach. Genes for this type of resistance are generally spread
through transformation. The other form of resistance is through the use of efflux pumps
that actively pump out the macrolide molecules. These pumps remove the macrolide from
the cytoplasm before it has a chance to disrupt protein synthesis. The genes for this type
of resistance are found on plasmids as well as large transposons (Leclercq, 2002).

Fluoroquinolones
Fluoroquinolones, also known as quinolones, have a bicyclic structure that
contains a fluorine atom. Examples of fluoroquinolones include ciprofloxacin, ofloxacin,
levofloxacin, enrofloxacin, danofloxacin, and orbifloxacin (Picó & Andreu, 2006). They
are active against Gram-positive and Gram-negative bacteria as well as mycobacteria.
Fluoroquinolones are broad-spectrum antibacterials that are used in both human and
veterinary medicine to treat a wide variety of bacterial diseases. In humans,
fluoroquinolones are used to treat urinary tract infections, digestive tract infections, and
respiratory infections. Some specific diseases that are targeted are typhoid caused by
Salmonella and pneumonia (Pham et al., 2019). Fluoroquinolones are important in
veterinary medicine, especially in the treatment of septicemias, respiratory, and enteric
diseases (OIE, 2021). Fluoroquinolones are listed on the WHO’s list of antimicrobials
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important for human medicine and the OIE’s list of antimicrobials as critically important
(OIE, 2021; WHO, 2019).

Mechanism of Action
All cells need to be able to synthesize DNA in order to divide, and bacteria are no
exception. The mechanism of fluoroquinolones involves interfering with bacterial DNA
synthesis by inhibiting two topoisomerase enzymes, DNA gyrase and topoisomerase IV.
These two enzymes are involved in the unwinding of DNA so that the replication
machinery can access the DNA molecule (Blondeau, 2004). If these enzymes cannot
function, the bacterial cell cannot separate its DNA, which prevents DNA replication.
Without DNA replication, the bacterial cell cannot divide to make more cells, which
limits its growth and leads to its death.

Resistance
Bacteria can develop resistance to fluoroquinolones through two main
mechanisms. The first is through alteration of the structure of DNA gyrase and
topoisomerase IV. A mutation in even one single amino acid sequence of these enzymes
leads to decreased ability of the fluoroquinolone to bind and inhibit the enzyme. If the
fluoroquinolone cannot bind to the enzyme, then it cannot inhibit DNA synthesis (Pham
et al., 2019). Another form of resistance relies on decreasing the concentration of
fluoroquinolones in the cytoplasm. This can be done by reducing the ability of
fluoroquinolones from entering the cell through decreased porin structures. Efflux pumps
can also be used to remove the fluoroquinolone once it has already entered the cytoplasm.
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Several genes related to both types of resistance can be found on plasmids, allowing for
horizontal gene transfer between bacteria (Pham et al., 2019).
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ANTIPARASITICS

Antiparasitics are a class of antimicrobials that kill or inhibit the growth of
parasitic organisms, which includes endoparasites like helminths and protozoa, as well as
ectoparasites, such as arthropods. The two antiparasitic classes reviewed in this paper are
the quinolines and avermectins, which are used in both human and veterinary medicine.

Quinolines
Quinolines are antiparasitics that are derived from the quinoline molecule.
Examples of quinolines include chloroquine, hydroxychloroquine, quinine, and
mefloquine. In human medicine, they are primarily used to treat and prevent malaria,
which is caused by a protozoan. They are also used to treat several autoimmune disorders
including rheumatoid arthritis and systemic lupus erythematosus (Schrezenmeier &
Dörner, 2020). Quinolines can also be used in veterinary medicine for the treatment of
some autoimmune diseases in dogs (Oberkirchner et al., 2011). Chloroquine is also used
in fish to treat and prevent some protozoal diseases (Hemdal, 2020).

Mechanism of Action
For part of its lifecycle, the protozoan that causes malaria, Plasmodium, breaks
down the hemoglobin of host red blood cells in order to acquire nutrients. This occurs in
the protozoal food vacuole. One of the by-products, heme, is toxic to the organism and is
normally detoxified by being converted into a crystalline structure called hemozoin.
Quinolines prevent the detoxification of heme by binding to the heme and preventing the
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protozoan’s enzymes from acting on it. The free heme can then destabilize the food
vacuole’s membrane and enter the cytoplasm. From there, several effects can cause the
organism’s death. Heme is capable of inhibiting protein function, disrupting membranes,
and creating reactive oxygen molecules that can damage DNA, proteins, and lipids
(Sigala & Goldberg, 2014).

Resistance
One of the most studied quinolines is chloroquine. Resistance to chloroquine
relies on the organism’s ability to decrease the amount of chloroquine that accumulates in
the food vacuole, though the exact mechanism of this ability is not known. One proposed
mechanism is the use of efflux pumps that actively remove the quinoline molecules.
Another possible mechanism is that less quinoline accumulates in the first place. This
could be due to changes in pH difference between the vacuole and the cytoplasm which
would reduce the amount of chloroquine that enters the food vacuole. Finally, decreased
chloroquine concentrations could be due to changes in the proteins involved in the
transport of the quinoline into the cell that decrease the amount of chloroquine that enters
(Foley, 1998).

Avermectins
Avermectins have a 16-membered macrocyclic lactone structure and have
antiparasitic activity. They were first isolated from the bacteria Streptomyces avermitilis
(Shoop et al., 1995). Ivermectin, abamectin, doramectin, eprinomectin, moxidectin, and
selamectin are all avermectins. These compounds have anthelmintic and insecticidal
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properties (El-Saber Batiha et al., 2020). In human medicine, avermectins are used to
treat river blindness, various roundworm infections, whipworm, lice, and mites. In
veterinary medicine, avermectins are used to treat and prevent infections caused by
roundworms, lungworms, heartworms, mites, lice, and ticks (Crump & Omura, 2011).

Mechanism of Action
Avermectins target the nervous system of parasites in order to paralyze them. The
nervous and muscular systems rely on the movement of ions through voltage-gated ion
channels to create electrical impulses. Avermectins bind to glutamate-gated chloride
channels, which are found only in invertebrates (Wolstenholme, 2012). By binding to
these channels, avermectins prevent the channel from closing and let more chloride into
the cell. This keeps the cell’s cytoplasm more negative and prevents the formation of an
electrical signal. As the organism can no longer move, it eventually dies (Lenz et al.,
2021). Avermectins also have the potential to bind to other channels, such as GABAgated chloride channels, which are present in both invertebrates and vertebrates. This can
lead to potential adverse side effects in the patient, particularly at high doses (Chen &
Kubo, 2017). Early uses of ivermectin were associated with extreme neurotoxicity in
some collie dogs due to their genetics. Some dog breeds, such as collies, have a deletion
mutation of the mdr1 gene, which allows the ivermectin molecules to cross the bloodbrain barrier. As this mutation also leads to increased sensitivity to other drugs, genetic
testing before treatment in these breeds, as well as other species, is becoming
increasingly common (Mealey et al., 2001).
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Resistance
There are two main mechanisms of resistance to avermectins. The first is through
mutations in the genes coding for glutamate-gated chloride channels, which would result
in a different structure for these channels. This different structure makes it less likely that
avermectins can bind to the receptors and affect the organism (Chen et al., 2016). The
other mode of resistance is through the metabolism of avermectins into a less toxic
chemical. If the avermectin is metabolized quickly enough, this prevents the molecule
from exerting its effect (Riga et al., 2014). The organisms that survive can then pass the
genes that confer resistance to their offspring.
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ANTIMICROBIAL USE DURING THE COVID-19 PANDEMIC

The COVID-19 pandemic has had a profound effect on the healthcare system, and
antimicrobial stewardship programs were no exception. These programs were disrupted
by changes in clinical service delivery, antimicrobial supply chain changes, and
overtreatment of COVID-19 patients with antibacterials (Lynch et al., 2020). While
COVID-19 is caused by a virus, there has been an increase in the use of antibacterials and
antiparasitics in the treatment of COVID-19 patients. Antibacterials are commonly
prescribed to those with a viral infection either because they were misdiagnosed or to
treat or prevent a bacterial infection. A bacterial co-infection is a bacterial infection that
is present in conjunction with another infection, such as a viral infection. A bacterial
secondary infection is an infection that occurs after the first infection. Bacterial
secondary infections occur with viral infections because these infections can weaken the
immune system and disrupt mechanisms to prevent infection (Langford et al., 2020). The
lack of treatment options for COVID-19 has also led to increased use of certain
antiparasitics including ivermectin and hydroxychloroquine because of their possibly
antiviral properties.

Changes in Antibacterial Use
The COVID-19 pandemic coincided with an increase in antibacterial use since
antibacterials were commonly prescribed to individuals suffering from COVID-19.
Recent studies have found that 72% of COVID-19 patients were treated with
antibacterials, but only 7% had a bacterial co-infection (Lansbury et al., 2020; Rawson et
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al., 2020). A study in the United Kingdom found that out of 49,000 patients, 37% were
prescribed antibacterials before they were even admitted to a hospital and 85% received
at least one antibacterial while in the hospital (Kuehn, 2021). Figure five demonstrates
the increase in antibacterial prescriptions in hospitals at the beginning of the COVID-19
pandemic (CDC, 2021a).

Figure 5. Antibacterial use during the COVID-19 pandemic compared to 2019 (CDC,
2021a)

The increase in antibacterial use is likely due to a variety of factors. The main
symptoms of COVID-19 are nonspecific and can be attributed to a number of respiratory
diseases, some of which are caused by bacteria. This combined with a lack of a
diagnostic test for COVID-19 at the beginning of the pandemic made it difficult for
healthcare providers to rule out the possibility of a bacterial infection and led to increased
use of antibacterials (Pulia et al., 2020). A study that surveyed 166 participants from
twenty-three countries found that the decision to prescribe antibacterials to COVID-19
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patients was made mainly on the presentation of clinical symptoms rather than lab tests
(Beović et al., 2020). There were also concerns regarding bacterial co-infections and
secondary infections with COVID-19 because these infections are relatively common
with other viral respiratory diseases. For example, bacterial co-infections can occur in as
many as 20-30% of severe influenza cases (Langford et al., 2020). In contrast, a review
of 3,338 patients with COVID-19 found that only 3.5% had a bacterial co-infection and
only 14.3% developed a bacterial secondary infection (Langford et al., 2020). The
reasons behind this discrepancy have not been well studied. Since COVID-19 was a
novel infection, healthcare providers had to make prescribing judgments without research
on the prevalence of bacterial co-infections in COVID-19 patients, which contributed to
the overuse of antibacterial use. Other factors that likely impacted antibacterial use were
the increased workload on prescribers and the severity of COVID-19. A lack of specific
guidelines for the treatment of COVID-19 combined with a dangerous and highly
contagious disease hindered the effective use of antibacterials.

Changes in Antiparasitic Use
There has been a significant amount of research into possible treatments for
COVID-19. While antiparasitics are generally used to treat parasitic infections, some
antiparasitics also have antiviral properties. Studies have been done, and are still being
conducted, on the possible uses of hydroxychloroquine and ivermectin in treating
COVID-19, however, there is not enough evidence to support their use. Claims that
hydroxychloroquine can be used to treat COVID-19 rely on research that shows that
hydroxychloroquine can inhibit the binding of the SARS-CoV-2 virus to the host cell
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membrane in vitro (“Chloroquine or hydroxychloroquine”, 2021). While early
uncontrolled and non-peer-reviewed studies stated that hydroxychloroquine was effective
in treating COVID-19, subsequent randomized controlled studies have demonstrated that
hydroxychloroquine has no effect and can even be harmful (Udupa et al., 2021).
Similarly, the claims supporting the use of ivermectin are also not verified, and its
use can lead to serious medical complications (Zaheer et al., 2021). While ivermectin has
been shown to inhibit the replication of SARS-CoV-2 in cell cultures, doses of up to 100times higher than recommended for human use would be needed, negating any potential
positive effect (“Ivermectin, 2021). The use of ivermectin or hydroxychloroquine to treat
or prevent COVID-19 is not recommended by the FDA or the WHO.
Despite a lack of research, hydroxychloroquine was promoted as a COVID-19
treatment by prominent members of society, including President Trump. The CDC
reported that there was an eighty-fold increase in new hydroxychloroquine and
chloroquine prescriptions from March of 2019 to March of 2020 (Bull-Otterson et al.,
2020). Ivermectin prescriptions and sales have also significantly increased during the
pandemic. A 24-fold increase in outpatient retail pharmacy prescriptions of ivermectin
was seen. Figure six shows the estimated number of outpatient ivermectin prescriptions
from retail pharmacies This does not include the ivermectin sold over-the-counter for
veterinary applications, mail-orders, or non-oral formulations. There has also been a fivefold increase in ivermectin-related calls to the poison control center (Lind et al., 2021).
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Figure 6. Ivermectin prescriptions from retail pharmacies (Lind et al, 2021)
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IMPLICATIONS FOR VETERINARY MEDICINE

The COVID-19 pandemic had a major impact on antimicrobial use in human
medicine, and these changes have serious implications for antimicrobial use in veterinary
medicine. One of the implications is that changes in human medical use affect the
availability of these antimicrobials for veterinary applications. Increases in
hydroxychloroquine prescriptions for those with COVID-19 made it difficult for those
who needed it for malaria or autoimmune diseases to acquire it. As hydroxychloroquine
is also used to treat some autoimmune diseases in animals, owners of these animals likely
faced similar barriers. Also, many pharmacists started to decline prescriptions, including
those made out for dogs in fear that these prescriptions were questionable (Sullivan,
2020). Demand for hydroxychloroquine also caused prices to drastically increase for
chloroquine phosphate, which is used to treat and prevent protozoal infections in fish. In
some cases, prices went from ten dollars a bottle to five-hundred dollars (Rahhal, 2020).
An increase in ivermectin sales also made it difficult for people to acquire the drug to
treat their animals (Sinclair, 2021). The limited supply and increased prices of these
drugs may have had a negative impact on animal health as they were not available to treat
infections in animals.
Perhaps the most pressing issue related to antimicrobial use during the COVID-19
pandemic is the development of antimicrobial resistance. An increase in AMR infections
in humans can negatively impact animal health since production and companion animals
depend on humans for their healthcare. With increases in human healthcare costs, longer
hospital stays, and more serious infections, people may not have the resources available
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to care for their animals. Mechanisms of resistance may also be shared with the animal’s
microorganisms, or the pathogen itself may infect the animals. These factors could lead
to increases in disease and decreases in animal welfare.
As mentioned earlier, human, animal, and environmental health are closely
related, so antimicrobial resistance anywhere is a threat to antimicrobial effectiveness
everywhere. The increase in antibacterials in the treatment of individuals with COVID-19
may lead to an increase in antimicrobial resistance in bacteria. This increase in AMR is a
problem for veterinary medicine as well since humans and animals share many of the
same pathogens. Bacteria have also evolved mechanisms of sharing resistance between
each other. Even if resistance develops in non-pathogenic bacteria, these species can act
as a reservoir for antimicrobial resistance and transmit their genes to other more
problematic species. Antimicrobials are critical for human and animal health, and they
need to be used appropriately. Changes in antimicrobial use are expected in pandemics,
but adequate antimicrobial stewardship practices are still important. If we do not
conserve the effectiveness of antimicrobials, we will once again find ourselves in the
middle of a pandemic with no effective treatments. In order to reduce the development of
antimicrobial resistance, the use of antimicrobials should be reduced. More emphasis
should be put on using treatments that do not rely on antimicrobials and conducting
culture sensitivity tests when antimicrobials must be used to ensure that the antimicrobial
will be effective.
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CONCLUSIONS

The COVID-19 pandemic had a dramatic effect on antimicrobial stewardship
practices in human health. There were increases in the use of antibacterials and
antiparasitics in particular. These increases in the use of antimicrobials in human
medicine have impacted veterinary medicine as well. The availability of these
antimicrobials for veterinary use was decreased through a lack of supply and increased
prices. The increased use of antimicrobials also has the potential to accelerate the
development of resistant organisms. Antimicrobial resistance is a serious concern for
human, veterinary, and environmental health. Antimicrobials need to be used in a
responsible way that preserves their effectiveness and maintains human, animal, and
environmental health.
One of the factors that may impact the effective use of antimicrobials, specifically
antibacterials, is medical professionals’ fear that they will be sued for malpractice for not
prescribing an antibacterial. Estimates place the risk of a physician being sued during
their lifetime between 75% and 99% (Jena et al. 2011). In addition to the financial costs
associated with legal defense, the physician can also suffer damage to their reputation. In
order to prevent possible lawsuits, some medical professionals use defensive medicine
where they administer tests, treatments, or medications that may not be effective. An
example is when a physician prescribes an antibacterial against their own clinical
judgement. One study found that medical professionals respond to liability pressure by
prescribing more antibacterials and introducing a cap on noneconomic damages led to
them being 6% less likely to prescribe antibacterials (Panthöfer, 2016). For
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antimicrobials to be effectively used, the malpractice system needs to be revised to
adequately protect patients while ensuring that medical professionals can make the
decisions that they think are correct without outside pressure.
While antibacterials are incredibly important in treating bacterial diseases, there
are other options for the treatment of bacterial infections that should be emphasized and
used when possible. This helps to preserve the effectiveness of antibacterials for when
they are truly necessary. The first step should always be preventing the disease through
vaccinations and reducing the risk of contracting the disease. If the patient has already
contracted the disease, there are options besides the use of antibacterials. One is the use
of lytic bacteriophages, which are viruses that specifically target bacteria. They can be
highly specific and target certain bacterial species (Opal, 2016). There are also drugs that
were developed to block toxin formation by Gram-positive species, such as
Staphylococcus aureus, which allows for the immune system to clear out the now
harmless bacteria. Also, since toxin production is not necessary for the bacteria to
survive, there is less selective pressure to lead to the development of resistance to the
drug (Greenberg et al., 2018). Other options include drugs that stimulate the immune
system and decrease the immune response as well as neutralizing antibody therapies.
The world is more connected through the internet and other media than at any
other time in history, which allowed for more communication at a faster rate during the
COVID-19 pandemic than during previous pandemics. The increase in communication
also has the possibility to affect antimicrobial use, which was seen during the COVID-19
pandemic. The increased access to information has allowed for people to access more
information regarding treatments for COVID-19 that were not yet adequately studied,
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including the use of ivermectin and hydroxychloroquine to treat COVID-19. In order to
prevent harm caused by the use of non-approved drugs, there needs to be an increase in
education and regulation of drugs. Medical professionals should be educated on the risks
of prescribing non-approved drugs and the general public should also be educated about
the importance of the correct use of drugs. It would also be helpful if the public was
educated on how to evaluate research and new articles to determine their validity. Finally,
media outlets should ensure that they are reporting accurate information and including the
risks associated with what they are talking about.
While technological advances in communication have led to some issues
regarding antimicrobial use, they have also helped to accelerate research. Research could
be shared more quickly which allowed for new research to be utilized more effectively by
a larger group of people. During the COVID-19 pandemic, the drug discovery and
approval process was prominently covered in the news as companies worked to develop
vaccines and treatments for this new disease. The FDA worked to update and streamline
its drug approval processes and created the Coronavirus Treatment Acceleration Program
to increase the speed of drug approval for the treatment of COVID-19 (FDA, 2022).
This review has highlighted ways in which the COVID-19 pandemic affected
antimicrobial stewardship in human medicine and how these changes have and could
impact veterinary medicine. Further studies should investigate how the pandemic directly
affected stewardship in veterinary medicine, whether the pandemic led to an increase in
antimicrobial resistance, developing new guidelines for antimicrobial use in regard to
COVID-19, and improving stewardship programs to reduce the possible impact future
pandemics have on stewardship practices.
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